Capecitabine for the treatment of advanced gastric cancer
Norman G, Soares M, Peura P, Rice S, Suh D, Wright K, Sculpher M, Eastwood A
Record ID 32011000919
English
Authors' recommendations:
The submission was considered to contain convincing evidence of the non-inferiority of capecitabine to 5-FU on the outcomes of OS and PFS; this evidence was considered to beapplicable to UK practice. There was evidence of some differences in adverse event profiles, but there was no evidence of a poorer safety profile for capecitabine overall. There was also no evidence of any difference in QoL between the two fluoropyrimidines.Although some uncertainty remains over the issues identified above, the ERG deems CMA to be an appropriate framework with which to analyse the current decision problem. Overall, cost estimates for the CMA were generated appropriately and were robust to uncertainties regarding assumptions and sources.
Details
Project Status:
Completed
Year Published:
2010
URL for published report:
http://www.hta.ac.uk/2174
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
England, United Kingdom
MeSH Terms
- Capecitabine
- Antineoplastic Combined Chemotherapy Protocols
- Deoxycytidine
- Fluorouracil
- Palliative Care
- Prodrugs
- Stomach Neoplasms
Contact
Organisation Name:
NIHR Health Technology Assessment programme
Contact Address:
NIHR Journals Library, National Institute for Health and Care Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK
Contact Name:
journals.library@nihr.ac.uk
Contact Email:
journals.library@nihr.ac.uk
Copyright:
2010 Queen's Printer and Controller of HMSO
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.